摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 3-(1,3-benzodioxol-5-yl)-4-(1-methyl-5-{[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]sulfonyl}-1H-pyrazol-3-YL)butanoate | 721920-91-8

中文名称
——
中文别名
——
英文名称
ethyl 3-(1,3-benzodioxol-5-yl)-4-(1-methyl-5-{[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]sulfonyl}-1H-pyrazol-3-YL)butanoate
英文别名
Ethyl 3-(1,3-benzodioxol-5-yl)-4-[1-methyl-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethylsulfonyl]pyrazol-3-yl]butanoate
ethyl 3-(1,3-benzodioxol-5-yl)-4-(1-methyl-5-{[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]sulfonyl}-1H-pyrazol-3-YL)butanoate化学式
CAS
721920-91-8
化学式
C27H32N4O6S
mdl
——
分子量
540.64
InChiKey
SWOOKYSUIZSQBQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    38
  • 可旋转键数:
    11
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.44
  • 拓扑面积:
    130
  • 氢给体数:
    1
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    ethyl 3-(1,3-benzodioxol-5-yl)-4-(1-methyl-5-{[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]sulfonyl}-1H-pyrazol-3-YL)butanoate盐酸 作用下, 以 丙酮 为溶剂, 生成 3-(1,3-benzodioxol-5-yl)-4-(1-methyl-5-{[2-(5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-2-YL)ETHYL]SULFONYL}-1H-PYRAZOL-3-YL) butanoic acid
    参考文献:
    名称:
    Synthesis of pyrazoles and isoxazoles as potent αvβ3 receptor antagonists
    摘要:
    We describe a series of pyrazole and isoxazole analogs as antagonists of the 043 receptor. Compounds showed low to sub-nanomolar potency against alpha(v)beta(3), as well as good selectivity against alpha(IIb)beta(3). In HT29 cells, most analogs also demonstrated significant selectivity against alpha(v)beta(6). Several compounds showed good pharmacokinetic properties in rats, in addition to anti-angiogenic activity in a mouse corneal micropocket model. Compounds were synthesized in a straightforward manner from readily available glutarate precursors. (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2006.03.045
  • 作为产物:
    参考文献:
    名称:
    Synthesis of pyrazoles and isoxazoles as potent αvβ3 receptor antagonists
    摘要:
    We describe a series of pyrazole and isoxazole analogs as antagonists of the 043 receptor. Compounds showed low to sub-nanomolar potency against alpha(v)beta(3), as well as good selectivity against alpha(IIb)beta(3). In HT29 cells, most analogs also demonstrated significant selectivity against alpha(v)beta(6). Several compounds showed good pharmacokinetic properties in rats, in addition to anti-angiogenic activity in a mouse corneal micropocket model. Compounds were synthesized in a straightforward manner from readily available glutarate precursors. (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2006.03.045
点击查看最新优质反应信息

文献信息

  • [EN] PYRAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES<br/>[FR] COMPOSES DE PYRAZOLE EN TANT QU'ANTAGONSITES DES RECEPTEURS DE L'INTEGRINE
    申请人:PHARMACIA CORP
    公开号:WO2004058761A1
    公开(公告)日:2004-07-15
    The present invention relates to pharmaceutical compositions comprising compounds of the Formula (I), and methods of selectively inhibiting or antagonizing the αVβ3 and/or the α Vβ5 integrin without significantly inhibiting the α Vβ6 integrin.
    本发明涉及包含式(I)化合物的制药组合物,以及选择性地抑制或拮抗αVβ3和/或αVβ5整合素的方法,而不显著抑制αVβ6整合素。
  • Pyrazole compounds as integrin receptor antagonists derivatives
    申请人:Penning D. Thomas
    公开号:US20050004200A1
    公开(公告)日:2005-01-06
    The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the α V β 3 and/or the α V β 5 integrin without significantly inhibiting the α V β 6 integrin.
    本发明涉及一类由公式I表示的化合物或其药学上可接受的盐,包括由公式I的化合物组成的药物组合物,以及选择性地抑制或拮抗αVβ3和/或αVβ5整合素而不显著抑制αVβ6整合素的方法。
  • PYRAZOLE COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES
    申请人:Pharmacia Corporation
    公开号:EP1572691A1
    公开(公告)日:2005-09-14
  • Synthesis of pyrazoles and isoxazoles as potent αvβ3 receptor antagonists
    作者:Thomas D. Penning、Albert Khilevich、Barbara B. Chen、Mark A. Russell、Mark L. Boys、Yaping Wang、Tiffany Duffin、V. Wayne Engleman、Mary Beth Finn、Sandra K. Freeman、Melanie L. Hanneke、Jeffery L. Keene、Jon A. Klover、G. Allen Nickols、Maureen A. Nickols、Randall K. Rader、Steven L. Settle、Kristen E. Shannon、Christina N. Steininger、Marisa M. Westlin、William F. Westlin
    DOI:10.1016/j.bmcl.2006.03.045
    日期:2006.6
    We describe a series of pyrazole and isoxazole analogs as antagonists of the 043 receptor. Compounds showed low to sub-nanomolar potency against alpha(v)beta(3), as well as good selectivity against alpha(IIb)beta(3). In HT29 cells, most analogs also demonstrated significant selectivity against alpha(v)beta(6). Several compounds showed good pharmacokinetic properties in rats, in addition to anti-angiogenic activity in a mouse corneal micropocket model. Compounds were synthesized in a straightforward manner from readily available glutarate precursors. (c) 2006 Elsevier Ltd. All rights reserved.
查看更多